Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Cellular and Phenotypic Plasticity in Cancer
The process of Epithelial-Mesenchymal-Transition (EMT) is known to result in a phenotype change in cells from a proliferative state to a more invasive state. EMT has been reported to drive the metastatic spread of various cancers and has also been associated with drug resistance to cytotoxics and targeted therapeutics. Recently phenotype switching akin to EMT has been reported in non-epithelial cancers such as metastatic melanoma. This process involves changes in EMT-Transcription Factors (EMT-TFs), suggesting that phenotype-switching may be common to several tumour types. It remains unclear as to whether the presence of both Epilthelial-like and Mesenchymal-like cells are a pre-requisite fo...
Regulation of Membrane Na+-K+ ATPase
Na+-K+ ATPase or Na-pump ATPase, a member of “P”-type ATPase superfamily, is characterized by association of multiple isoforms mainly of it’s α- and β- subunits. At present four different α- (α-1,α-2,α-3 and α-4) and three β- (β-1, β-2, and β-3) isoforms have been identified in mammalian cells and their differential expressions are tissue specific. Regulation of Na+-K+ ATPase activity is an important but a complex process, which involves short-term and long-term mechanisms. Short-term regulation of Na+-K+ ATPase is either mediated by changes in intracellular Na+ concentrations that directly affect the Na+-pump activity or by phosphorylation/dephosphorylation-mediated by some...
The Literature of Weimar Classicism
New essays providing an account of the shaping beliefs, preoccupations, motifs, and values of Weimar Classicism.
A Milestone in Frontiers in Pharmacology: 1,000 Published Papers in the Section Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology was launched in 2010, with a number of sections which were eventually reorganized. The founding Field Chief Editor was Prof. Théophile Godfraind, an eminent scientist active in cardiovascular pharmacology, who pioneered the discovery of calcium antagonists. At that time he invited me to serve as Chief Editor for a section named “Analytical and Experimental Pharmacology”. Later on, our section enlarged and was re-named as “Experimental Pharmacology and Drug Discovery” to outline the translational potential of fundamental pharmacological research and theoretical analysis to the improvement of human health, through the invention of novel medicinal products. We are now entering the 10th year of editorial activity, which sees the publication of the 1,000th paper in our section. Such an achievement is very rewarding for us and our community, but it is even more remarkable when placed into the timeline of our development. In fact, in a 10-year frame we have significantly grown in quantity and quality, e.g. both in number of published papers and in scientific impact. [From a personal perspective by Salvatore Salomone, Specialty Chief Editor]
The Tumor Microenvironment
This second edition provides update and new chapters detailing core and emerging in vitro and in vivo protocols. Chapters guide readers through cellular and molecular biology approaches, in vivo genetic approaches, various “omics”-based strategies, therapeutic strategies, and advanced techniques in the fields of tissue engineering and nanotechnology. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and thorough, The Tumor Microenvironment: Methods and Protocols, Second Edition is a valuable resource for both novice and expert scientists in this developing field.
Drug Repositioning: Current Advances and Future Perspectives
Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.
